Information Provided By: 
Fly News Breaks for November 19, 2015
TTPH
Nov 19, 2015 | 06:30 EDT
SunTrust upgraded Tetraphase to Buy and increased its price target to $21 from $12 on shares. Analyst Edward Nash believes the Street is not currently placing any value for eravacycline in cUTI. Nash said, following additional analyses from the IGNITE 2 study, he is encouraged by the by the efficacy signal and has added back to his eravacycline model the cUTI indication and European Union revenue, which he removed after the negative top-line data from IGNITE 2.
News For TTPH From the Last 2 Days
There are no results for your query TTPH
